Heuristic Optimization of Antibody Production by CHO

Heuristic Optimization of Antibody Production by CHO
Heuristic Optimization of Antibody Production by CHO

NOTES

Heuristic Optimization of Antibody Production by Chinese Hamster Ovary Cells

Sandeepa Sandadi,Semsi Ensari,*and Brian Kearns

Biotechnology Development,Schering-Plough Research Institute,1011Morris Avenue,Union,New Jersey07083 Large-scale production of monoclonal antibodies necessitates the development of a

commercially viable process using the appropriate bioreactors,culture medium,and

optimal feeding strategies.In the development of feeding strategies for higher antibody

titers it is critical to assess the effects of limiting substrates on cell culture longevity

and antibody production.In this study,glucose and L-glutamine were identified as

limiting substrates and their effects on culture longevity and antibody production were

evaluated in small-scale experiments.The results suggested that an optimal feeding

strategy should account for the osmolality profile of the culture.The heuristic approach

taken to optimize the antibody production showed that the fed-batch cultivation is

superior to batch culture and maintaining low osmolality during growth phase

increases cumulative viable cell density and thus leads to higher final antibody titer.

Introduction

Cultured mammalian cells are widely used for the production of potential therapeutics.The use of optimal feeding strategies and culture medium,in addition to appropriate bioreactors,enhances the yield of the anti-body product.A typical fed-batch operation involves feeding the nutrients necessary for cell growth,the precursors for product formation,or the inducers.

For most animal cells glucose and L-glutamine are the major sources of carbon and nitrogen,respectively.The metabolism of both glucose and L-glutamine is inter-related,and the proportion of each nutrient consumed by the different cellular pathways depends on the meta-bolic state of the cells(1).Therefore,their effect on culture longevity and antibody production needs to be studied when developing feeding strategies.The signifi-cance of glucose and L-glutamine for growth and main-tenance of Chinese hamster ovary(CHO)cells has been extensively studied.In a recent study,Sun et al.(2) showed that L-glutamine cannot support recombinant CHO cell growth and maintenance in the absence of glucose.Subsequently,the metabolism of CHO cells at low glucose concentrations was investigated by determin-ing intracellular metabolites.It was observed that the shortage of energy from reduced glucose metabolism resulted in cellular growth limitation,and amino acid catabolism could not replenish the energy deficit(3). Alternatively,a large glucose addition leads to significant changes in the osmolality of the culture.This is particu-larly true in bioreactors,where the osmolality of the culture increases as a result of two reasons,base addi-tions to control the pH and glucose additions to supply necessary energy for the culture.Past studies emphasized the importance of osmolality on cell culture and antibody production.Among various methods to increase antibody production,hyperosmolality has been recognized as an economical solution(4-9).Moreover,in a fed-batch culture,repeated feeding of medium concentrates leads to a substantial increase in medium osmolality(10).In addition to antibody production,elevated osmolality can also affect growth rate,duration of exponential growth, and cell death rate.However,within a range of osmolality (300-400mOsm/kg),an increased specific antibody production rate can compensate for a decreased growth rate and cell concentration to yield a higher final antibody concentration(11).Previously,a few culture strategies were developed to optimize antibody production using the osmolality dependence of the cultures(6,9).In contrast, Zhu et al.(12)observed that increased specific productiv-ity in hyperosmolal batch culture did not result in a significant improvement in final titer because of sup-pression of cell growth.Therefore,the effects of osmolality on the culture should also be considered when interpret-ing the effects of glucose in the development of feeding strategies for the bioreactors.

With the availability of a limited number of bioreactors, there have been intensive efforts to develop microbio-reactor systems to diminish scale-up problems.Addition-ally,recent studies showed that shake flasks can be modified to mimic conventional stirred tank systems(13, 14).Previous studies also investigated the feasibility of using shake flasks to culture animal cells and verified their scalability to larger volumes(15,16).Although bioreactors offer a controlled environment for process parameters,it is very difficult to maintain constant levels of pH and dissolved oxygen in shake flasks.Therefore, the coupled effects of pH control and osmolality in the bioreactors should be considered when interpreting the results of shake flask experiments.

*To whom correspondence should be addressed.Ph:(908)820-6354.Fax:(908)820-6995.E-mail:semsi.ensari@https://www.360docs.net/doc/993164718.html,.1537

Biotechnol.Prog.2005,21,1537?1542

10.1021/bp0501266CCC:$30.25?2005American Chemical Society and American Institute of Chemical Engineers

Published on Web07/27/2005

In shake flasks,statistically designed experiments

provide effective and efficient ways to investigate the

effects of factors on response variables.The sequential

and predictive nature of these designs allows greater

understanding of the effects of these factors on culture

performance when compared to the classical one-factor-

at-a-time approach and can detect potential interactions

among the factors.When experimenting with known

factors,their effects and interactions have to be first

estimated using factorial designs,followed by response

surface methods to optimize the response(17).On the

other hand,when only a few factors are under investiga-

tion,an alternative approach is to skip factorial designs.

The response surface graph generated from the effect of

two or more quantitative factors may provide useful

information to develop experimental strategies.In the

past,response surface methods were used for rational

optimization of culture media and/or operating conditions

of both microbial and cell cultures.In contrast,the use

of response surfaces to develop heuristic strategies for

bioreactor optimization has not been reported.In this

study,the effects of limiting nutrients and osmolality on

culture longevity and antibody production were investi-

gated in shake flasks using response surface methods.

Because the shake flask experiments do not allow for

rational optimization of cultivations in bioreactors,the

results from the response surface for antibody production

were interpreted to develop and test heuristic osmolality

profiles to improve final antibody titer in bioreactors.

Materials and Methods

Cell Line and Culture Conditions.CHO dihydro-

folate reductase(DHFR)-deficient mutant cell line DXB-

11expressing a proprietary recombinant protein was

propagated in shake flasks at37°C with7.5%CO2

overlay at100rpm using protein-free,animal-component-

free CHO medium(Sigma C5467,St.Louis,MO)con-

taining4g/L glucose and supplemented with4mM L-glutamine.Cellbags(Wave Biotech LLC,Bridgewater, NJ)for inoculum were cultured at37°C with7.5%CO2

overlay,and the platform rocker was set at10rocks per

minute with an angle of8°.Cultures were passaged in

their exponential phase of growth using split ratios of

1:3,1:4,or1:5to achieve seeding densities around0.3×

106cells/mL.

Offline Measurements.Samples were analyzed for

viable and total cell counts by Cedex System(Innovatis

AG,Bielefeld,Germany),glucose/lactate and L-glutamine/ L-glutamate by YSI2700Select(YSI Inc.,Yellow Springs, OH),pH/pO2/pCO2by ABL5(Radiometer America Inc., Westlake,OH),NH4+by Nova BioProfile100Plus(Nova Biomedical Corp.,Waltham,MA),and osmolality by Advanced Micro-Osmometer(Advanced Instruments, Norwood,MA).The antibody content of the culture supernatant samples was quantified by a reverse-phase chromatography assay that was based upon a reported technique(18).The liquid chromatography system(Agi-lent1100system,Palo Alto,CA)was equipped with an R2/10Poros column(30mm×2.1mm,Applied Biosys-tems,Cambridge,MA).The column temperature was maintained at70°C.The flow rate was initially set at 0.1mL/min until the column temperature stabilized at 70°C,and it was set to2mL/min during all gradient segments.Solution A was0.2%trifluoroacetic acid in water,and Solution B was0.2%acetic acid in aqueous acetonitrile(90:10).The gradient program started with 0.5min at32%Solution B followed by a5-min gradient from32%to60%Solution B.Consequently,a1-min gradient to100%Solution B was followed by a1-min gradient back to32%Solution B.The program was

finished by a2-min equilibration at32%Solution B.The

detection was carried out at280nm by either a photo-

diode array detector or a multiwavelength detector using

5-100μL injections depending on the titer of the culture.

The linear range for the assay is from0.2to2.5μg of

antibody and the assay variability is3%.

Response Surface Methods.Response surface graphs

visualize the effects of two factors very effectively.Box

and Wilson(19)introduced central composite design

(CCD)as an alternative to3n factorials to estimate

quadratic response surface equations where n is the

number of https://www.360docs.net/doc/993164718.html,D consists of2n factorial points with

2n additional treatment combinations called axial points

and m replications at the center of the design.The

designs used in this study were rotatable and contained

eight factorial points,four axial points,and four center

points(Design-Expert,Version6.0.10,Stat-Ease,Inc.,

MN).In rotatable designs the variance of estimated

values is constant at points equally distant from the

center point(uniform precision).Two sets of response

surface designs were used to observe the effects of

glucose,L-glutamine,and osmolality on the culture

longevity and antibody production.First,the effects of

glucose and L-glutamine were investigated,using a range

of glucose concentrations between1and15g/L and L-glutamine concentrations between0.5and14.5mM. Second,the effect of osmolality was studied using NaCl

and glucose,with NaCl concentrations between0and83

mM and glucose concentrations between4and16g/L.

No KCl was supplied along with NaCl in order to mimic

base control in the bioreactors,which is accomplished

with sodium-containing bases only.All experiments were

carried out in250-mL shake flasks containing72(5mL

culture.The cultures were incubated at37°C with7.5%

CO2overlay at100rpm and sampled on days0,1,2,3,

4,5,10,and15.The response variables were final

antibody titer and the cumulative viable cell density

(CVC)calculated using the trapezoidal rule for the

integral given by

where t f is the final time.The values are reported as

percent of maximum.

Bioreactor Operating Conditions.Celligen Plus

bioreactors(3L working volume,H/D) 1.2:1,New

Brunswick Scientific Co.,Inc.,Edison,NJ)were run at

37°C,with a constant gas sparging rate of0.03vvm,and

agitated by marine blade impellers at250rpm.The

bioreactors were equipped with a condenser to minimize

any evaporative losses due to off-gas.The dissolved

oxygen was maintained by controlling the composition

of the inlet gas mixture consisting of air,nitrogen,

oxygen,and carbon dioxide.The pH was controlled at6.8

by carbon dioxide gas sparging and1M sodium hydroxide

addition.All cultures were inoculated with0.75L of seed

culture and filled up to a working volume of3L with L-glutamine and glucose-enriched protein-free,animal-component-free CHO medium(Sigma C5467,St.Louis, MO).Initial L-glutamine concentration was11.6mM.The initial glucose concentration in the batch culture was12 g/L,and glucose additions for the fed-batch cultures were done according to the heuristic approach described below. The working volume in fed-batch cultures remained constant as a result of the use of highly concentrated feeds.

Heuristic Optimization.To maximize the yield of the

cell culture,a heuristic approach was proposed by

CVC)∫0t f X d t(1)

manipulating initial glucose concentration and feeding profile.Mainly,two heuristics were developed using the response surface graph for the final antibody titer gener-ated from shake flask studies.In both heuristics,the glucose concentration was maintained between8and10 g/L by adding15mL of glucose solution(450g/L)when the concentration was less than8g/L.For the first heuristic(Heuristic1),initial glucose concentration was chosen at the point of maximum yield observed in the response surface for the final antibody titer(9g/L).The second heuristic(Heuristic2)was set up at the basal glucose concentration(4g/L).To maintain low osmolality profile during the growth phase,three gradually increas-ing bolus feeds were charged on days2,3,and4.Each bolus feed was calculated using the following equation to attain a glucose concentration of9g/L on day4: where V(t)is the amount of glucose to be added to the bioreactor on a given day t,V is the working volume(3 L),S F and S(t)are the glucose concentration in the feed (450g/L)and bioreactor,respectively.

Results and Discussion

The effects of glucose and L-glutamine were studied in shake flasks using response surface methods.To compare the results of the batch culture experiments,the two parameters considered were the final titer and CVC calculated by eq1.The values are reported as percent of maximum.

Response Surface Study1.The response surface graphs of the final antibody titer and CVC are depicted in Figure1as a function of initial L-glutamine and glucose concentration.In the top panel,the final antibody titer increased with increase in L-glutamine and glucose concentrations,suggesting that the two nutrients were limiting for the given system.On the other hand,the CVC was maximum at the center where the concentra-tions of L-glutamine and glucose were7.5mM and8g/L, respectively(see bottom panel).As indicated in Figure 1,when glucose and L-glutamine were increased from4 g/L glucose and4mM glutamine to8g/L glucose and 7.5mM glutamine,both final antibody titer and CVC increased by55%and12%,respectively.Although an additional increase in the initial concentrations of glucose and L-glutamine to12g/L and11.6mM,respectively, improved the final antibody titer further by23%,there

was an6%decrease in CVC.The specific productivity, defined as the ratio of final antibody titer to CVC, increased with increasing L-glutamine and glucose con-centrations.The enhanced specific productivity could also be due to increase in osmolality of the culture.Hence,it was vital to distinguish the effect of initial osmolality and glucose concentration,along with their interaction on the cell culture.

Response Surface Study2.To facilitate the under-standing of the effect of initial osmolality and glucose concentration on the cell culture,it was imperative to ensure that there was no L-glutamine limitation.The results from the first study indicated that L-glutamine at an initial concentration above11.6mM was not depleted during the15-day cultivation.Thus the initial L-glutamine concentration in the second study was chosen as11.6mM,and the range for initial glucose concentration was between4and16g/L.The results of the second response surface study are depicted in Figure 2as a function of initial NaCl and glucose concentrations. The highest final antibody titer was observed between8 and10g/L glucose concentration and40to44mM NaCl, which corresponds to400to420mOsm/kg osmolality(see top panel).Although the final titer showed a nonmono-tonic dependence on the osmolality,CVC decreased monotonically with increasing osmolality(see bottom panel).At the initial glucose concentration of10g/L,the final antibody titer improved by24%and the CVC decreased by30%as the osmolality of the culture increased from360to420mOsm/kg.The specific pro-ductivity in this case improved by77%,confirming that the specific productivity increases with increase in os-molality.Hence,the elevated titers observed in the shake flasks,at glucose concentrations greater than10g/L, were due to the effects of increased osmolality and not the effects of glucose,per se.It should however be noted

V(t))V(9-S(t))

S

F

(5-t)

(2)

Figure1.Response surface graph for the effect of glucose and

L-glutamine on the final antibody titer(top panel)and cumula-

tive viable cell density(bottom panel).The numbers of replicates

are depicted along with the design points as solid circles and

the final antibody titer and CVC values(%of maximum)are

shown by contour lines.

that this increase in titer was attained at the expense of CVC.Thus in a bioreactor,where the osmolality of the culture inherently increases with base and glucose ad-ditions,it would not be feasible to start at 420mOsm/kg osmolality as suggested from the shake flask experi-ments.In other words,both batch and fed-batch mode of operations in the bioreactor would be subjected to additional increase in osmolality due to base additions.This may in turn lead to a decrease in final titer as the increased specific productivity cannot compensate for the drastic decrease in CVC.However,the dependence of specific productivity on osmolality suggests that an appropriate osmolality profile may improve the titer in fed-batch operation of the bioreactors.

Heuristic Optimization.To maximize the final an-tibody titer,an optimal solution would maximize both CVC and specific productivity.Previously,biphasic cul-

ture strategies based on the osmotic stress improved the titers in batch cultures significantly (6,9).In this study,a heuristic approach was proposed to determine the “best”feasible solution by interpreting the results ob-tained from the response surface studies.The idea was to first maximize the cell growth by maintaining low osmolality and then maximize the specific productivity by gradually increasing the osmolality.Two heuristics were developed using the response surface graphs for the final titer generated from the shake flask studies.The details of the two heuristics are described in Materials and Methods.

The first response surface study in shake flasks indicated that the “best”culture condition for a batch bioreactor was 11.6mM L -glutamine and 12g/L glucose.This condition was selected as the Control culture for the bioreactors.The second response surface showed that the highest final antibody titer was between 8and 10g/L glucose concentration (see Figure 2)and 400to 420mOsm/kg osmolality.Hence,Heuristic 1started with 9g/L glucose concentration and was maintained between 8and 10g/L to gradually increase the osmolality during the cultivation.In addition,the second response surface study showed that whereas CVC was maximal at the basal osmolality,the specific productivity increased with increasing osmolality.The dependence of specific pro-ductivity and CVC on osmolality suggested that the final titer could be improved further,by first maximizing the cell growth at low osmolality and then increasing the osmolality gradually to maximize the final titer.Hence,Heuristic 2started at 4g/L basal glucose concentration and was charged with the three bolus feeds of glucose on days 2,3,and 4,to increase the osmolality gradually during the exponential phase.Thereafter Heuristic 2was also maintained between 8and 10g/L glucose concentra-tion,similar to Heuristic 1.

The glucose,osmolality,CVC,and titer profiles for three bioreactor runs are depicted in Figure 3.As intended,the glucose concentration for Heuristic 1was maintained between 8and 10g/L,whereas in Heuristic 2,glucose was fed on days 2,3,and 4to increase the osmolality gradually (see panel A).At the end of the cultivation Heuristics 1and 2had 26.5and 28.1g/L total glucose addition,respectively,whereas only 12g/L of glucose was added to the batch culture.It should be noted that the additional glucose was only used for increasing the osmolality of the culture and hence was not com-pletely utilized as an energy source.In accord with the initial glucose concentrations,all three cultures started at three different osmolalities.While the osmolality profile for the batch culture increased slightly,the profiles for both heuristics were similar after day 5(see panel B).This increase in osmolality in batch culture is due to lactate production and base addition for pH control.As depicted in panel C,CVC profile for Heuristic 2was higher than the other two cultures.As expected,the results are in accord with the low osmolality profile that Heuristic 2attained during growth phase.Similarly,Heuristic 2reached the highest titer among three cul-tures (see panel D).Overall,Heuristics 1and 2,respec-tively,reached approximately 10%lower and 20%higher values for both CVC and titer when compared to the Control culture.Therefore,overall specific productivities were similar for all the three cultures.While both Heuristic 1and 2attained osmolalities higher than that of the batch culture,all three cultures averaged similar osmolalities and specific productivities.Additionally,the Control culture in the bioreactor attained 25%higher specific productivity when compared to the shake

flask

Figure 2.Response surface graph for the effect of glucose and sodium chloride on the final antibody titer (top panel)and cumulative viable cell density (bottom panel).The numbers of replicates are depicted along with the design points as solid circles and the final antibody titer and CVC values (%of maximum)are shown by contour lines.

culture with the same initial conditions.The improved specific productivity could be mainly due to increase in osmolality as a result of base additions and partly due to strict dissolved oxygen and pH control in the bioreac-tor.The specific productivities of the Control culture remained almost constant for the duration of the cultiva-tion and the values increased slightly for Heuristic 1.On the other hand,in Heuristic 2,the specific productivity at the end of the cultivation was 50%higher than the specific productivity at the beginning.While there were significant differences in the CVC and titer,L -glutamine,lactate,and ammonium concentrations were similar in all the three cultures (data not shown).Consequently,the specific rates of L -glutamine consumption and lactate and ammonium production were lowest in the culture with gradual increase in osmolality (Heuristic 2).In summary,Heuristic 2,which experienced a gradual increase in the osmolality from the basal condition,improved the yield by approximately 20%as compared to the culture with quasi-steady osmolality profile.The results of the bioreactor runs were process significant since the typical batch-to-batch variability is within 4%.

Conclusions

The effects of glucose and L -glutamine on the culture were studied in shake flasks using response surface methods.The shake flask studies indicated that the best culture condition for a batch bioreactor was 11.6mM L -glutamine and 12g/L glucose.Increased specific pro-ductivity was observed with an increase in the concentra-tions of glucose and L -glutamine.However,to distinguish between the effects of increased glucose and osmolality

on the culture,a second response surface study was implemented by using a constant initial L -glutamine concentration of 11.6mM and varying the initial glucose and salt concentrations.Due to the strong dependence of specific productivity and CVC on the osmolality of the culture,a heuristic approach was adopted to maximize the final antibody titer by maximizing both CVC and specific productivity.The idea was first to maximize the viable cell density and then gradually increase the osmolality to maximize the antibody production.The heuristic profile improved the yield by approximately 20%as compared to the culture with quasi-steady osmolality profile.The results suggest that for biological systems,which display nonmonotonic behavior with respect to osmolality,the final titers can be further improved by maintaining low osmolality during the growth phase and then gradually increasing the osmolality with glucose/base additions during the late growth phase.

Acknowledgment

We thank Dennis Rendeiro and two anonymous reviewers for their comments.We also acknowledge Jack Cardoso,Mike Cuzzola,Carmine Giannetta,James Jimenez,Debbie Lutz,and Rich Stout for assistance with experiments and Steve Blaisdell,Brittany Larkin,and Ed Previte for performing reverse-phase analysis.

References and Notes

(1)Blanch,H.W.;Clark,D.S.Biochemical Engineering ;Marcel Dekker:New York,1997.

(2)Sun,X.;Zhang,Y.Glutamine cannot support recombinant CHO cell growth and maintenance in the absence of glucose.Process Biochem .2004,39,717-

720.

Figure 3.Time profiles of (A)glucose,(B)osmolality,(C)cumulative viable cell density,and (D)titer for the comparison of fed-batch (Heuristic 1and 2)and batch (Control)cultures.

(3)Lu,S.;Sun,X.;Zhang,Y.Insight into metabolism of CHO

cells at low glucose concentration on the basis of the deter-mination of intracellular metabolites.Process Biochem.2005, 40,1917-1921.

(4)deZengotita,V.M.,Miller,W.M.Characterization of

hybridoma cell response to elevated pCO2and osmolality: Intracellular pH,cell size,apoptosis,and metabolism.Bio-technol.Bioeng.2002,77,369-380.

(5)Kim,N.S.;Lee,G.M.Response of recombinant Chinese

hamster ovary cells to hyperosmotic pressure:effect of Bcl-2 overexpression.J.Biotechnol.2002,95,237-248.

(6)Kim,M.S.;Kim,N.S.;Sung,Y.H.;Lee,G.M.Biphasic

culture strategy based on hyperosmotic pressure for improved humanized antibody production in Chinese hamster ovary cell culture.In Vitro Cell.Dev.Biol.:Anim.2002,38,314-319.

(7)Lee,M.S.;Lee,G.M.Effect of hypoosmotic pressure on cell

growth and antibody production in recombinant Chinese hamster ovary cell culture.Cytotechnology2001,36,61-69.

(8)Ozturk,S.S.;Palsson,B.O.Effect of medium osmolarity

on hybridoma growth,metabolism,and antibody production.

Biotechnol.Bioeng.1991,37,989-993.

(9)Reddy,S.;Miller,W.M.Effects of abrupt and gradual

osmotic stress on antibody production and content in hy-bridoma cells that differ in production kinetics.Biotechnol.

Prog.1994,10,165-173.

(10)Bibila,T.A.;Ranucci C.S.;Glazomitsky,K.;Buckland,B.

C.;Aunins,J.G.Monoclonal antibody process development

using medium concentrates.Biotechnol.Prog.1994,10,87-

96.

(11)Hu,W.-S.;Aunins,https://www.360docs.net/doc/993164718.html,rge-scale mammalian cell

culture.Curr.Opin.Biotechnol.1997,8,148-153.(12)Zhu,M.M.;Goyal,A.;Rank,D.L.;Gupta,S.K.;Boom,T.

V.;Lee,S.S.Effects of elevated pCO2and osmolality on growth of CHO cells and production of antibody-fusion protein B1:A case study.Biotechnol.Prog.2005,21,70-77. (13)Liu,C.-M.;Hong,Li-Na.Development of a shaking bio-

reactor system for animal cell cultures.Biochem.Eng.J.

2001,7,121-125.

(14)Akgun,A.;Maier,B.;Preis,D.;Roth,B.;Klingelhofer,R.;

Buchs,J.A novel parallel shaken bioreactor system for continuous operation.Biotechnol.Prog.2004,20,1718-1724.

(15)Buchs,J.Introduction to advantages and problems of

shaken cultures.Biochem.Eng.J.2001,7,91-98.

(16)Gupta,A.;Rao,G.A study of oxygen transfer in shake

flasks using non-invasive oxygen sensor.Biotechnol.Bioeng.

2003,84,351-358.

(17)Anderson,M.J.;Whitcomb,P.J.RSM Simplified:Opti-

mizing Processes using Response Surface Methods for Design of Experiments;Productivity Press:New York,2005. (18)Battersby,J.E.;Snedecor,B.;Chen,C.;Champion,K.M.;

Riddle,L.;Vanderlaan,M.Affinity-reversed-phase liquid chromatography assay to quantitate recombinant antibodies and antibody fragments in fermentation broth.J.Chro-matogr.A2001,927,61-76.

(19)Box,G.E.P.;Wilson,K.G.On the experimental attain-

ment of optimum conditions.J.R.Stat.Soc.1951,B13,1-45. Accepted for publication June27,2005.

BP0501266

抗磷脂综合征诊断和治疗指南

史堡丛遑遁生苤查垫!!生鱼旦筮!』鲞箜§塑£h纽I基h!H幽!吐』女盟垫!!,yQ!:!£盟Q:§ 抗磷脂综合征诊断和治疗指南 中华医学会风湿病学分会 1概述 抗磷脂综合征(antiphospholipidsyndrome,APS)是一种非 炎症性自身免疫病,l临床上以动脉、静脉血栓形成,病态妊娠 (妊娠早期流产和中晚期死胎)和血小板减少等症状为表现, 血清中存在抗磷脂抗体(antiphospholipidantibody,aPL),上述 症状可以单独或多个共同存在。 APS可分为原发性APS和继发性APS,继发性APS多见 于系统性红斑狼疮(SLE)或类风湿关节炎(RA)等自身免疫 病(悉尼标准建议不用原发性和继发性APS这一概念,但目 前的文献多仍沿用此分类)。此外,还有一种少见的恶性APS (catastrophicAPS),表现为短期内进行性广泛血栓形成,造成 多器官功能衰竭甚至死亡。原发性APS的病因目前尚不明 确,可能与遗传、感染等因索有关。多见于年轻人。男女发病 比率为1:9,女性中位年龄为30岁。 2临床表现 2.1动、静脉血栓形成:APS血栓形成的临床表现取决于受 累血管的种类、部位和大小,可以表现为单一或多个血管累 及,见表1。APS的静脉血栓形成比动脉血栓形成多见。静脉 血栓以下肢深静脉血栓最常见,此外还可见于肾脏、肝脏和 视网膜。动脉血栓多见于脑部及上肢,还可累及肾脏、肠系膜 及冠状动脉等部位。肢体静脉血栓形成可致局部水肿,肢体 动脉血栓会弓l起缺血性坏疽,年轻人发生脑卒中或心肌梗死 应排除原发性APS可能。 2.2产科表现:胎盘血管的血栓导致胎盘功能不全,可引起 习惯性流产、胎儿宫内窘迫、宫内发育迟滞或死胎。典型的 APS流产常发生于妊娠lO周以后,但亦可发生得更早,这与 抗心磷脂抗体(anticardiolipinantibodv,aCL)的滴度无关。APS 孕妇可发生严重的并发症,早期可发生先兆子痫,亦可伴有 溶血、肝酶升高及血小板减少,即HELLP综合征。 2.3血小板减少:是APS的另一重要表现。 2.4APS相关的肾病:主要表现为肾动脉血栓/狭窄、肾脏缺 血坏死、肾性高血压、肾静脉的血栓、微血管的闭塞性肾病和 相关的终末期肾病统称为APS相关的肾病。 2.5其他:80%的患者有网状青斑,心脏瓣膜病变是晚期出 现的临床表现,严重者需要做瓣膜置换术。此外,APS相关的 神经精神症状包括偏头痛、舞蹈病、癫痫、吉兰一巴雷综合征、 一过性球麻痹等,缺血性骨坏死极少见。 3实验室检查 3.1aPL的血清学检查 DOI:10.37601cma.J.issn.1007-7480.2011.06.012 ?407? ?诊治指南?表1AlaS血栓的临床表现 3.1.1狼疮抗凝物(LA):LA是一种lgG/IgM型免疫球蛋白。作用于凝血酶原复合物(Xa、Va、Ca2+及磷脂)以及Tenase复合体(因子IXa、Via、Caz+及磷脂),在体外能延长磷脂依赖的凝血试验的时间。因此检测LA是一种功能试验,有凝血酶原时间(PT)、激活的部分凝血活酶时间(APTI')、白陶土凝集时间 (KCT)和蛇毒试验,其中以KCT和蛇毒试验较敏感。3.1.2acL:目前标准化的榆测方法是以心磷脂为抗原的间 接酶联免疫吸附试验(ELISA)法,国际上对I如和I州型的aCL的检测结果的表述单位为GPL(1斗咖l纯化的IgG型aCL的结合抗原活性)和MPL(1¨加nl纯化的IgM型aCL的

原发性抗磷脂综合征

原发性抗磷脂综合征 【概述】 抗磷脂综合征(Anti-phospholipid syndrome, APS)是一种非炎症性自身免疫病,临床上以动脉、静脉血栓形成、习惯性流产和血小板减少等症状为表现,血清中存在抗磷脂抗体(aPL),上述症状可以单独或多个共同存在。 APS可分为原发性抗磷脂综合征(PAPS)和继发性抗磷脂综合征(SAPS),SAPS多见于系统性红斑狼疮或类风湿关节炎等自身免疫病。此外,还有一种少见的恶性抗磷脂综合征(Catastrophic APS),表现为短期内进行性广泛血栓形成,造成多器官功能衰竭甚至死亡。PAPS的病因目前尚不明确,可能与遗传、感染等因素有关。多见于年轻人,男女发病比率为1:9,女性中位年龄为30岁。 【临床表现】 一、动、静脉血栓形成 APS血栓形成的临床表现取决于受累血管的种类、部位和大小,可以表现为单一或多个血管累及(见表1)。APS的静脉血栓形成比动脉血栓形成多见。静脉血栓以下肢深静脉血栓最常见,此外还可见于肾脏、肝脏和视网膜。动脉血栓多见于脑部及上肢,还可累及肾脏、肠系膜及冠状动脉等部位。肢体静脉血栓形成可致局部水肿,肢体动脉血栓会引起缺血性坏疽,年轻人发生中风或心肌梗死应排除PAPS可能。 二、产科 胎盘血管的血栓导致胎盘功能不全,可引起习惯性流产、胎儿宫内窘迫、宫内发育迟滞或死胎。典型的APS流产常发生于妊娠10周以后,但亦可发生得更早,这与抗心磷脂抗体(aCL)的滴度无关。APS孕妇可发生严重的并发症,早期可发生先兆子痫,亦可伴有溶血、肝酶升高及血小板减少,即HELLP(Hemolysis, Elevated Liver enzymes and Low platelets)综合症。 三、血小板减少 血小板减少是APS的另一重要表现。 四、其他 80%的病人有网状青斑,心脏瓣膜病变是后出现的临床表现,严重的需要做瓣膜置换术。此外可有神经精神症状,包括偏头痛、舞蹈病、癫痫、格林-巴利综合征、一过性球麻痹等,缺血性骨坏死极少见。 表1 APS的血栓临床表现 累及血管临床表现 静脉 肢体深静脉血栓 脑中枢静脉窦血栓 肝脏 小静脉肝肿大;转氨酶升高 大静脉Budd-Chiari综合征 肾脏肾静脉血栓 肾上腺中央静脉血栓;出血、梗死,Addison’s病 肺肺血管栓塞;毛细血管炎;肺出血;肺动脉高压大静脉上/下腔静脉综合征

单克隆抗体在肿瘤治疗中的应用

单克隆抗体在肿瘤治疗中的应用 抗体分子是生物学及医学领域中用途最为广泛的蛋白质分子。利用传统的免疫方法或通过细胞工程和基因工程技术制备的抗肿瘤特异性抗原、肿瘤相关抗原、独特型决定簇、某些细胞因子受体、激素及一些癌基因产物的多克隆抗体、单克隆抗体或基因工程抗体等使肿瘤的被动免疫治疗发生了改观。人们可以用单抗单独应用于肿瘤治疗,也可以以单抗为特异性载体而将与其偶联的放射性核素、抗癌药物、毒素、酶和其他类型生物制剂“携运”至肿瘤部位,发挥相应的抗瘤效应,这种免疫偶联物亦称为“生物导弹”。 人们最初期望用类似于抗感染的被动免疫方法来治疗肿瘤,即用特异性的同种或异种抗血清或患同类肿瘤“痊愈”病人的血清注射给肿瘤病人。由于人类肿瘤细胞抗源性、肿瘤细胞异质性等诸多理论上的问题未能解决,因而要获取特异性强且效价高的抗肿瘤抗血清很不现实。直到20世纪70年代中期B 淋巴细胞杂交瘤技术的建立,人类在这领域的研究才向前迈进一大步。B淋巴细胞与鼠的骨髓瘤细胞融合,在选择性培养基的条件下,筛选出杂交瘤细胞,筛选出的杂交瘤细胞继承了其亲代细胞的性质,既可分泌抗体,又能无限传代。由特异抗原致敏的某个B细胞克隆所产生的抗体即为单克隆抗体。这种由杂交瘤技术制备的单抗是杂交瘤细胞所分泌的抗体,其质地均一,纯度高,效价高,且能重复大量生产。由于单克隆抗体特异性高,能在多种抗原中识别特异性抗原决定簇,已帮助人类鉴定出多种肿瘤相关抗原,但某种肿瘤是否存在特异性抗原至今未获普遍认同。 目前认为单抗的作用机制有阻断作用、信号传导作用以及靶向作用等三种作用机制:11阻断作用 现用于临床的大部分未偶联单抗主要用于自身免疫和免疫抑制,是通过阻断和调节作用完成的。几乎在所有的单抗应用中,通常都是通过阻断免疫系统的一种重要的胞浆或受体-配体相互作用而实现的。另一种相类似的阻断活性可能存在于单抗的抗病毒感染中,通过阻断和抵消病原体的进入和扩散表现出对机体的防御功能,短期给予单抗后可取得长期疗效。21信号传导作用许多抗癌单抗是通过恢复效应因子,直接启动信号机制而获得细胞毒效应的。在抗-Id的临床试验中,B细胞受体(BCR)与抗体的交联导致正常细胞和肿瘤细胞的生长受抑制和凋亡。对trastuaumab而言,单抗结合可诱导一系列在肿瘤生长控制中起作用的信号传递,该抗原是生长因子受体家族的一个成员,能提供重要的有丝分裂信号,其单抗似乎能阻断与促进肿瘤生长有关的重要的配体-受体相互作用。31靶向作用单抗靶向肿瘤细胞的首要目的是产生肿瘤特异性反应物,然后由免疫系统中的活化因子将其消灭,如早期抗-Id单抗在淋巴瘤中的应用。研究表明:利用单抗与化学药物、放射性核素以及毒素形成的偶联物具有对肿瘤细胞的选择性杀伤作用,同时具有更高的疗效,并且对耐药性肿瘤细胞也有杀伤作用。这些研究结果为应用于肿瘤治疗的可行性提供了重要依据。单克隆抗体用于抗肿瘤治疗有2种基本的方式,一是单抗的单独应用,二是

1单克隆抗体药物----科普知识

1 单克隆抗体药物----科普知识 单克隆抗体药物 2009-10-19 15:47 1986年,美国FDA批准了第一个单克隆抗体药物上市,距今已经整整20年了。截止到现在,全世界共有21个治疗用抗体药物被批准上市,实现300亿美元的销售额,在国际,也在国内形成了抗体药物开发热潮。巨大的市场前景和现存的技术问题及壁垒并存的现实不可避免地引发抗体药物新一轮技术革命。而其结果又将毫无疑问地改变抗体药物的市场格局。抗体药物的研究开发能否真能成为中国生物技术药物开启国际市场大门的新钥匙?什么是我们首选的切入点,又如何形成我们自己的特色和竞争优势?回顾国际抗体药物20年风雨飘摇的发展经历,总结其中的经验教训无疑会给我们一些有益的启示。 1986年,美国FDA批准上市了第一个抗体药物Orthoclone,用于治疗移植物抗宿主病(GVHD),翻开了生物医药历史崭新的一页。时隔8年,美国才批准了第二个抗体药物上市。进入21世纪,抗体药物研发上市的速度明显加快。20年后的今天,全球共批准上市21个抗体药物。进入临床验证的数量也直线上升,从上个世纪80年代的70个,到90年代新增140个,以及2000年至2005年6月又增加的130个,预计2010年将再增 240个【1】,显示抗体药物研究异常活跃。目前共有150余个抗体药物正在临床评估中,其中16个已进入III期临床【2】。 抗体药物研发进展迅速及竞争激烈的主要原因是1)抗体药物具有高度特异性,是靶向治疗的基础,在这一方面远优于小分子药物;2)虽然在世界范围内20年仅仅批准上市了21个抗体药物,事实上其淘汰率仍明显低于小分子药物,临床转化率以及批准成功率都较高,以治疗癌症的抗体药物为例,其批准成功率为29%;3)抗体药物即使在专利保护到期后,由于其生产条件的复杂性,也很难受到通用名药价格的威胁;4)更为重要的是已上市的抗体药物具有很高的市场回报率,大大刺激了投资热情。目前,上市抗体药物中已盈利的有8个,其中4个已经成为年销售额10亿美元以上的“重磅弹”,5个销售总额超过30亿美元【3】。预计2005-2010年抗体药物销售的平均增长率为20%,年销售额将超过300亿美元,市场潜力巨大。 但具有讽刺意味的是,从药物经济学的角度看,抗体药物并非很好的药物候选者。首先,单克隆抗体是大分子糖蛋白,结构复杂、不利储存、不能口服、进入体内5-7天才能到达靶位置。其次,抗体药物研发费用较高,达10-18亿美元,高于小分子药物平均研发费的9亿美元。第三,目前抗体药物的单剂用量大,药物的质量标准高,生产成本高昂,导致价格昂贵,以致被喻为“经济负作用”。以治疗肿瘤的抗体药物Avastin为例,单个病人年度费用高达5万美元【4】。然而,正在形成的巨大市场是抗体药物研发的不竭驱动力。 我国在单克隆抗体技术起步非常早,80年代曾出现过研究热潮,但产业化成就还微不足道。目前,受国际抗体研发进展的影响,又出现了新一轮的“抗体热”,北京、上海、广州等纷纷成立了由研究机构、企业和投资商的联合抗体研发中心和公司。面对国际抗体药物竞争的新态势,我国抗体药物产业是否遇到了真正的机遇?我们选择的切入点是什么,又如何形成自己的特色和竞争优势?抗体药物的研究开发能否成为中国生物技术药物开启国际市场大门的新钥匙?回顾国际抗体药物20年风雨飘摇的发展经历,总结其中的经验教训无疑会给我们一些有益的启示,这是本文的主要目的。 一、上市抗体药物的发展现状 从第一个抗体药物上市至今20年内,全球共批准了21个抗体药物,其中美国18个(包括9个被欧盟

什么是抗磷脂抗体综合征

什么是抗磷脂抗体综合征 在我们的生活中,有各式各样的疾病,他们也有很多学名,也许我们看到这样的病知道他是什么症状,但是让你叫出他的学名,估计没多少人能叫出来。还有些人去药店买药,医师问他需要什么药,连他自己也不知道要买什么药,说不出具体药的名称,所以呢,只好跟医师说了发病的症状,医师就根据他所说的症状给他开了药。那什么是抗磷脂抗体综合征?怎么治? 什么是抗磷脂抗体综合征?怎么治?经调查,知道这个学名的人寥寥无几,也没多少人关注这个,但是他跟我们的生活息息相关,下面是医学界给出我们这样的概念,什么是抗磷脂抗体综合征?怎么治? 抗磷脂抗体综合征(antiphospholipid syndrome,APS)是指由抗磷脂抗体(antiphospholipid antibody,APL抗体)引起的一组临床征象的总称。APL抗体是一组能与多种含有磷脂结构的抗原物质发生免疫反应的抗体,主要有狼疮抗凝物(lupus anti-coagulant,LA)、抗心磷脂抗体(anti-cardiolipid antibody,ACL抗体)、抗磷脂酸抗体和抗磷脂酰丝氨酸抗体等。与APL抗体有关的临床表现,主要为血栓形成、习惯性流产、血小板减少和神经精神症状等,APS是SLE病人中常见的临床表现

从上述的概念中我们可以知道什么是抗磷脂抗体综合征了,那么怎么治呢?下面我们详细介绍: 1.西医治疗治疗的主要目标是抑制血栓形成包括抗血小板、抗凝、促纤溶等。 (1)抗血栓形成治疗:急性期为阻断血栓形成可用肝素治疗。对有动静脉血栓者可口服抗凝剂对已用足量华法林抗凝仍有反复血栓形成者可皮下注射足量肝素,2次/d,使PTT 延长至正常值的1.5~2倍,或采用免疫抑制剂(环磷酰胺)、激素、肝素和华法林抗凝联合治疗。 (2)针对流产治疗:每天小剂量阿司匹林(60~80mg)口服和肝素5000~10000单位皮下注射,2次/d可使APS中的妊娠得以改善。为防止长期肝素治疗所致的骨质疏松,辅以维生素D和钙剂;对肝素无效或副作用明显者, 可每月按0.4g/(kg?d)静脉滴注γ球蛋白4~5天,同时口服小 剂量阿司匹林;泼尼松20~60mg/d加小剂量阿司匹林能成功地 防止流产但只是在其他治疗失败时用。长期大剂量激素对妊娠、胎儿不利。流产一旦确诊为APS所致后以小量阿司匹林,疗效明显。 2.中医治疗中医治疗抗磷脂抗体综合征主要是辨证论治, 分型治疗。常见有气虚血瘀、气滞血瘀和寒凝血瘀三型。分别应用益气养血活血化瘀、舒肝理气活血化瘀和温经补肾活血化瘀法

副肿瘤综合征

副肿瘤综合征 概述 副肿瘤综合征(paraneoplastic syndrome)是发生在某些恶性肿瘤患者体内,在未出现肿瘤转移的情况下即已产生能影响远隔自身器官功能障碍而引起的疾病。它并不是由肿瘤直接侵犯该组织或器官而产生的一组症状。副肿瘤综合征可影响到体内的许多组织和器官,造成相应的临床表现,如关节炎、皮疹、内分泌功能紊乱等。影响的远隔自身器官如在神经系统则称之为神经系统副肿瘤综合征(neurologic paraneoplastic syndrome),如肌病、神经肌肉接头病、神经根病变、周围神经病变、脊髓以及大脑的病变等。中枢神经系统副肿瘤综合征的发生率比较低,较转移瘤少见(1-2%)。但由此综合征所造成的损害,而出现的临床表现要较肿瘤本身更早,并更为严重,因而,在临床上需要对此有高度的重视,这对恶性肿瘤的早期诊断也具有重要的意义。 早在1888年,Oppenheim描述了1例恶性肿瘤合并周围神经病的病例。此年他又描述了1例淋巴肉瘤合并球麻痹,认为是第一例中枢神经系统的远隔效应。Auche (1890年)报道了胃、胰腺、子宫的恶性肿瘤合并周围神经病。Guichara (1956年)提出了副肿瘤综合征这一名词。从此后在国内、外陆续有许多文献报道副肿瘤的各种不同的临床类型。 神经系统副肿瘤综合征可累及神经系统的任何部位,因此,在临床上会有许多种神经系统副肿瘤综合征的临床表现。它可以累及中枢神经系统产生弥漫性灰质脑病、小脑变性、癌性脊髓病及边缘系统脑炎等,可以累及周围神经系统产生多发性神经病、复合性单神经炎以及累及神经肌肉接头而产生重症肌无力、Lambert-Eaton肌无力综合征、神经性肌强直及皮肌炎/多发性肌炎等。副肿瘤综合征可以仅累及单一神经或肌肉中的某一结构(如小脑的蒲肯野氏细胞,肌肉的胆碱能突触)出现单一的临床表现,前者表现为小脑性共济失调,后者为肌无力综合症。有时临床表现为一单独的神经系统损害,但是其病理改变却比较广泛,不过仍以其中一个结构损害的症状为主要突出的表现。 病因和发病机制 副肿瘤综合征的病因和发病机制目前并不十分清楚。以前普遍认为可能由于癌肿分泌某些直接损害神经系统的物质,如分泌激素样物质(hormone-like substances)和细胞因子(cytokines)。肿瘤产生的激素样物质可引起高钙血症、无力以及行为异常。肿瘤产生的异位ACTH造成的Cushing’s Syndrome和行为异常。白细胞介素-1和肿瘤坏死因子可造成肌肉萎缩和无力。 目前认为免疫因素肯定是十分重要的发病因素之一。肿瘤抗原引起对肿瘤本身的抗原抗体反应,产生大量的抗体。这种抗体可以与神经系统内的某些类似抗原性的成分发生交叉性免疫反应,这种交叉性免疫反应既抑制肿瘤的生长,使肿瘤变小或生长缓慢,但也损害了神经系统,造成神经功能障碍。如Lambert-Eaton 肌无力综合征的患者中大约有2/3的患者同时合并有小细胞性肺癌,因肿瘤产生的特异性免疫球蛋白IgG与小细胞肺癌细胞的钙通道,以及与胆碱能突触处的钙通道均能产生免疫反应。故在胆碱能突触处的IgG与钙通道的反应,阻止了动作电位到达突触时的钙内流,使乙酰胆碱释放减少,产生肌无力症状群。血浆置换后Lambert-Eaton肌无力综合征患者血清中的IgG被去除,患者症状得以恢复。此血浆直接接种于实验动物也可造成肌无力。 副肿瘤综合征患者血清和脑脊液中可发现某些抗体,这些抗体与癌肿或损

单克隆抗体制备与应用

单克隆抗体制备与应用 姓名:王志豪学号:10073485 班级:工优070 关键词:单克隆抗体,人抗体,杂交瘤细胞 摘要:1975年德国学者Kohler和英国学者Milstein成功地将骨髓瘤细胞和产生抗体的B淋巴细胞融合为杂交瘤细胞,其分泌的抗体是由识别一种抗原决定簇 的细胞克隆所产生的均一性抗体,称之为单克隆抗体。从鼠源单抗之后,单抗历经了鼠源性抗体、嵌合抗体、人源化抗体、人源性抗体4个发展阶段。随着分子生物学和细胞生物学的发展,单抗理论几乎应用到生物学研究的每一个区域。 1975 年, Kohler 和Milstein 创立了杂交瘤技术制备单克隆 抗体,此后单克隆抗体迅速广泛地应用于生物学和医学的各个领域。单克隆抗体可用于分析抗原的细微结构及检验抗原抗体未知的结构 关系;生产出针对复杂生物混合物中的特定分子的抗体,可用于分离、分析及纯化该特定分子抗原;其试剂可用于临床诊断和治疗,或用于 以单抗为弹头的“生物导弹”药物等。但单克隆抗体技术自问世以来,在临床治疗方面进展缓慢,主要原因是目前单克隆抗体大多是鼠源性的,而鼠源单抗应用于人体治疗时存在诸多问题:鼠源单抗在人体中 常不能有效激活补体和Fc 受体相关的效应系统;被人体免疫系统所 识别,产生人抗鼠抗体(HAMA) 反应;且在人体循环系统中很快被清除。因此,在保持对特异抗原表位的高亲和力的基础上人源化和全人化的改造,减少异源抗体的免疫原性成为单抗研究的重点。此外,传统杂交瘤技术还存在制备周期较长,成本较高,杂交瘤细胞不稳定抗性会丢

失等缺陷。近年来,随着分子生物学技术的发展,出现了嵌合单克隆抗体和由转基因小鼠、噬菌体展示技术、核糖体展示技术及共价展示技术所制备的单克隆抗体。这些技术可有效解决传统杂交瘤技术所存在的问题,为单克隆抗体的应用提供更广阔的空间。 1994 年, 美国Cell Genesys 公司和Genpharm公司宣布转基因小鼠作为生产全人抗体的载体问世。这项技术是将人抗体基因微位点转入小鼠体内,产生能分泌人抗体的转基因小鼠。其前提是人的抗体基因片段在小鼠体内进行重排并表达,并且这些片段能与小鼠细胞的信号机制相互作用,即在抗原刺激后,这些片段可被选择、表达并活化B 细胞分泌人抗体。这些转基因小鼠的不足之处在于转移基因片段较小,仅30kb 左右,因此这种抗体库在面对抗原多样性时,其抗体应答显得单薄而不足。此后,Green 等人利用基因打靶技术将编码人抗体轻重链的基因片段大约18Mb 的DNA 全部转到自身抗体基因位点已被灭活的小鼠基因组中,再经过繁育筛选,建立了稳定的转基因小鼠品系。这样得到的转基因小鼠对特异的抗原能产生高亲和力的人抗体。用传统的杂交瘤技术,将表达特异抗体的转基因小鼠B 细胞和骨髓瘤细胞融合,获得杂交瘤细胞系,产生人源抗体。利用转基因小鼠技术已获得了一系列抗IL8 、TNFα以及EGFR 的人单克隆抗体,这些细胞因子在肿瘤或其他疾病中起着重要的作用,因此其单克隆抗体作为导向剂具有重要的临床治疗意义。目前生产的单抗大多是鼠源性的,但其在临床应用方面还存在着很大的弊端,主要是鼠源单抗与NK 等免疫细胞表面Fc 段受体亲和力弱,产生的抗体依赖性细胞介导的细胞毒

原发性抗磷脂综合征诊疗指南

原发性抗磷脂综合征诊疗指南 【概述】 抗磷脂综合征(Anti-phospholipid syndrome, APS)是一种非炎症性自身免疫病,临床上以动脉、静脉血栓形成、习惯性流产和血小板减少等症状为表现,血清中存在抗磷脂抗体(aPL),上述症状可以单独或多个共同存在。 APS可分为原发性抗磷脂综合征(PAPS)和继发性抗磷脂综合征(SAPS),SAPS多见于系统性红斑狼疮或类风湿关节炎等自身免疫病。此外,还有一种少见的恶性抗磷脂综合征(Catastrophic APS),表现为短期内进行性广泛血栓形成,造成多器官功能衰竭甚至死亡。PAPS的病因目前尚不明确,可能与遗传、感染等因素有关。多见于年轻人,男女发病比率为1:9,女性中位年龄为30岁。 【临床表现】 一、动、静脉血栓形成 APS血栓形成的临床表现取决于受累血管的种类、部位和大小,可以表现为单一或多个血管累及(见表1)。APS的静脉血栓形成比动脉血栓形成多见。静脉血栓以下肢深静脉血栓最常见,此外还可见于肾脏、肝脏和视网膜。动脉血栓多见于脑部及上肢,还可累及肾脏、肠系膜及冠状动脉等部位。肢体静脉血栓形成可致局部水肿,肢体动脉血栓会引起缺血性坏疽,年轻人发生中风或心肌梗死应排除PAPS可能。 二、产科 胎盘血管的血栓导致胎盘功能不全,可引起习惯性流产、胎儿宫内窘迫、宫内发育迟滞或死胎。典型的APS流产常发生于妊娠10周以后,但亦可发生得更早,这与抗心磷脂抗体(aCL)的滴度无关。APS孕妇可发生严重的并发症,早期可发生先兆子痫,亦可伴有溶血、肝酶升高及血小板减少,即HELLP(Hemolysis, Elevated Liver enzymes and Low platelets)综合症。 三、血小板减少 血小板减少是APS的另一重要表现。 四、其他 80%的病人有网状青斑,心脏瓣膜病变是后出现的临床表现,严重的需要做瓣膜置换术。此外可有神经精神症状,包括偏头痛、舞蹈病、癫痫、格林-巴利综合征、一过性球麻痹等,缺血性骨坏死极少见。 表1 APS的血栓临床表现 累及血管临床表现 静脉 肢体深静脉血栓 脑中枢静脉窦血栓 肝脏 小静脉肝肿大;转氨酶升高 大静脉Budd-Chiari综合征 肾脏肾静脉血栓 肾上腺中央静脉血栓;出血、梗死,Addison’s病 肺肺血管栓塞;毛细血管炎;肺出血;肺动脉高压 大静脉上/下腔静脉综合征 皮肤网状青紫;皮下结节 眼视网膜静脉血栓 动脉 肢体缺血性坏死

单克隆抗体在肿瘤治疗中的应用

单克隆抗体在肿瘤治疗中的应用 【摘要】单克隆抗体在一段相当短的时间内成为治疗癌症的主流方法。它们的第一个用途是作为致癌受体酪氨酸激酶受体拮抗剂,但今天单克隆抗体已成为长期寻求的有效化疗药物靶向递送的载体并作为操纵抗癌免疫反应的功能的强大的工具。在临床上有更加可喜的成果,未来将有可能看到持续增长治疗性抗体和它们的衍生物的发展。 由于单克隆抗体药物专一性强、疗效显著,为抗肿瘤治疗开辟了一条新的途径,因此成为近年来研究的热点药物之一。单克隆抗体抗体是由B 淋巴细胞转化而来的浆细胞分泌的,每个B淋巴细胞株只能产生一种它专有的、针对一种特异性抗原决定簇的抗体。这种从一株单一细胞系产生的抗体就叫单克隆抗体,简称单抗。这些抗体具有相同的结构和特性。抗体与特异性表达的肿瘤细胞表面蛋白质结合,从而阻碍蛋白质的表达,起到抗肿瘤作用。抗体还可使B 淋巴细胞产生免疫反应,诱导癌细胞凋亡。早期单抗为鼠源性单抗,易被人体免疫系统识别,应用受到限制。后来采用基因工程的方法生产人源或人鼠嵌合型单抗,广泛应用于临床。 单抗药物治疗主要是利用其靶向性来干预肿瘤发生发展过程中的各个通路,或是激活宿主对肿瘤的免疫等。随着生物医学的不断发展,一定会出现具有更高靶向性的单抗药物。但是,单抗药物还存在一些尚未解决的问题,最突出的问题是如何降低单抗的免疫原性,单抗的异源性所引起的抗体反应,不但降低了单抗的效价,而且会给患者带来严重的后果。因此,对异源性单抗进行改造以及人源性单抗的研制成为单抗研究的重要方向 1.EGEG疗法 表皮生长因子受体EGFR是一种细胞表面蛋白,与多种癌症密切相关,也是癌症治疗的主要靶标。基因编码信息被翻译为特定蛋白,不过,许多蛋白必须经由翻译后程序激活,比如自身磷酸化。蛋白激活影响着许多重要的细胞过程,包括细胞增殖、分化和迁移。若EGFR 出现故障使这些过程脱离控制,就会导致癌症。然而,尽管EGFR与癌症有着密切关联,人们对EGFR的激活机制还并不完全了解。 受体酪氨酸激酶是一个细胞表面受体大家族,EGFR也是其中一员。EGFR有一个细胞外的配体结合域,和一个细胞内的激酶区域。EGFR激活是其配体EGF结合到配体结合域,诱导受体二聚化,随后二聚体的两个激酶区域相互磷酸化。因为在相对较低的浓度下,即使没有EGF诱导的二聚化,单独的激酶域在溶液中也能自激活。二聚化是指两个同样的分子聚合形成单个化合物。研究发现,除了配体EGF结合以外,EGFR激活还需要EGFR跨膜螺旋和

单克隆抗体的制备

单克隆抗体的制备 摘要:单克隆抗体技术是现代生命科学研究的重要工具,在基因和蛋白质的结构和功能研究方面有着不可或缺的作用。近年来,随着分子生物学技术的发展,出现了嵌合单克隆抗体和由转基因小鼠、噬菌体展示技术、核糖体展示技术及共价展示技术所产生的单克隆抗体。这些技术将有效解决单克隆抗体的鼠源性等问题。下面主要讲述制备单抗的实验过程。 关键词:抗体,单克隆,肿瘤,细胞融合,淋巴细胞 现代生物技术制药工业始于1971年,现已创造出35个重要治疗药物,全球大约有2500多家公司,主要产品有重组蛋白质药品、重组疫苗和诊断、治疗用的单克隆机体三大类。我国自80年代在采用现代生物技术改造传统生物技术制药产业方面已取得初步成果。但我国生物技术诊断试剂、酶工程、动植物细胞工程医药产品、现代生物技术支撑技术、后处理技术和制剂技术等方面与国外还存在差距。 1.国外现代生物技术产业发展的现状 自1971年Cetus公司成立至今,现代生物技术制药工业已走完了二十五年的路程,创造出35个重要的治疗药物,目前已在治疗癌症、多发性硬化症、贫血、发育不良,糖尿病、肝炎、心力衰竭、血友病、囊性纤维变性和一些罕见的遗传性疾病中取得良好效果。在医药工业中,传统生物技术(包括近代生物技术)已为人类提供了许多重要药品,在保障人类生命健康和推动社会进步中发挥了巨大作用;现代生物技术以其特有的高新技术又为人类提供了传统生物技术难以获得的极微量的珍贵药品。由于这一系列现代生物技术新型药物的出现,使过去无法治疗的疑难疾病得到了治疗。同时,应用现代生物技术DNA重组,细胞融合以及细胞大规模培养等现代生物技术发展和提高传统生物技术的生产水平,为抗生素、氨基酸、维生素以及基体激素等药品的生产,构建了高产新菌株,创造新工艺,提高生产能力,降低生产成本,促进生产发展。

抗磷脂综合征诊断标准

抗磷脂综合征最新诊断标准 临床标准 1.血管栓塞:至少有一次经影像学、超声多普勒或组织学证实的任何脏器或器官的动脉、静脉或小血管血栓形成发作 2.怀孕异常 (1)至少1次不能解释的孕10周或10周以上的胎儿死亡,或 (2)至少1次因先兆子痫、子痫或严重胎盘功能不全导致孕34周或34周以上的早产(新生儿形态正常),或 (3)3次或3次以上的孕10周前自发流产 实验室标准 1.抗心磷脂抗体:2次中高滴度的IgG或/和IgM型抗体阳性(间隔至少12周) 2.狼疮抗凝物:2次阳性(间隔至少12周) 3.抗β2GPI抗体:2次高滴度IgM或IgG型抗体阳性(间隔至少12周) 至少1条临床标准和至少1条实验室标准即可确诊 附原文: Diagnostic Criteria for APS Clinical criteria 1.Vascular thrombosis:At least one episode of arterial, venous, or small-vessel thrombosis in any tissue or organ confirmed by imaging, Doppler ultrasound, or histopathology 2.Pregnancy morbidity (1)At least one unexplained fetal death at or beyond 10 wk, or (2)At least one premature birth of morphologically normal neonate at or beyond 34 wk due to preeclampsia, eclampsia, or severe placental insufficiency, or (3)Three or more spontaneous pregnancy losses before 10 wk of gestation Laboratory criteria 1.Anticardiolipin antibodies: medium- or high-titer IgG and/or IgM on two occasions at least 12 wk apart 2.Lupus anticoagulant: on two occasions at least 12 wk apart 3.Detection of anti-β2GPI antibodies: high-titer IgM or IgG on two occasions at least 12 wk apart

单抗类抗肿瘤药物概述

单抗类抗肿瘤药物概述 单抗类抗肿瘤药物单抗类抗肿瘤药物作用机制为当机 体受抗原刺激时,抗原分子上的许多决定簇分别激活各个具有不同基因的B 淋巴细胞。 被激活的B 细胞分裂增殖形成效应B 细胞(浆细胞)和记忆B 细胞,大量的浆细胞克隆合成和分泌大量的抗体分子分布到血液、体液中。如果能选出一个制造一种专一抗体的浆细胞进行培养,就可得到由单细胞经分裂增殖而形成细胞群,即单克隆。 单克隆细胞将合成针对一种抗原决定簇的抗体,称为单克隆抗体。单克隆抗体以其高特异性、有效性和低毒性,可以准确地攻击靶分子, 且毒副作用较低,已成为一类重要的抗肿 瘤药物。单克隆抗体抗肿瘤机制包括:免疫介导的效应功能,包括抗体依赖性细胞介导的细胞毒性反应(ADCC)和补体依 赖性细胞毒性反应(CDC)。单抗与肿瘤细胞靶抗原特异性结合后,其Fc段可以与NK细胞、巨噬细胞和中性粒细胞等 效应免疫细胞表面的Fc受体(FcR)结合,激活细胞内信号,发挥效应功能。NK细胞通过释放细胞毒性颗粒(穿孔素和颗粒酶)导致靶细胞的凋亡;释放细胞因子和趋化因子抑制细胞增殖及血管生成。 巨噬细胞可以吞噬肿瘤细胞,有释放蛋白酶、活性氧和细胞

因子等加强ADCC作用。此外,一些偶联抗体通过连接细胞毒化合物或放射性物质来杀伤肿瘤细胞,如TDM1(trastuzumab emtansine)、Zevalin等。1997-2013年FDA 和CFDA批准的抗肿瘤单抗类药物列表如图15。图15:1997-2013年FDA和CFDA批准的抗肿瘤单抗类药物(点开大图观看更清晰?)截至目前,全球上市的单克隆抗体共51个,其中鼠源单克隆4个、嵌合抗体7个、人源化单克隆抗体23个、全人单克隆抗体17个。单抗药物中,抗肿瘤药物占了一半左右。截至目前,中国上市的抗肿瘤单抗类药物共有7个,其中进口4个,国产3个,国内自主研发的第一个单克隆抗体类抗肿瘤药物为百泰药业治疗鼻咽癌的药物尼妥珠单抗(泰欣生)2008年4月被正式批准联合放疗治疗EGFR表达阳性的Ⅲ/Ⅳ期鼻咽癌(比埃克替尼早了3年),这是全球第一个以EGFR为靶点的人源化单抗药物。2015年,中国国内单抗药物销售额约为72亿元人民币,其中肿瘤药占了80%,约为57亿元,同比约占全球抗药市场的1.13%。对比小分子靶向药物,2014年国内22重点城市样本医院靶向小分子抗肿瘤药物市场为13.21亿元,根据2015年样本医院全年靶向小分子药物购入金额为14.92亿元,占全球市场的1.34%。 从全球市场上看,2015年靶向抗肿瘤药物TOP10中有6个是单抗,前3名全是单抗,且销售额差距明显,前3名2015

妊娠合并抗磷脂抗体综合症

妊娠合并抗磷脂抗体综合症 抗磷脂综合征(antiphospholipid syndrome,APS)是由抗磷脂抗体(antiphospholipid antibody,APA)引起,主要表现为血栓形成、血小板减少、习惯性流产、早发型重度子痫前期等一组临床症候群。临床上根据有无合并其他自身免疫性疾病,将APS分为原发性抗磷脂综合征(primary antiphospholipid syndrome,PAPS)和继发性抗磷脂综合征(secondary antiphospholipid syndrome,SAPS)。SAPS多见于系统性红斑狼疮患者,还可以继发于类风湿性关节炎、干燥综合征、强制性脊柱炎等其他自身免疫性疾病。另外还有一种较少见的APS,称为暴发性抗磷脂综合征(catastrophic antiphospholipid syndrome,CAPS),在APS中的发病率低于1%,常在短期内出现多器官功能衰竭,病死率高于50%。 一、诊断: 1、病史:反复流产,胎儿生长受限,妊娠中、晚期原因不明的胎死宫内,早发型重度子痫前期,血小板减少,血栓形成,自身免疫疾病或胶原病,自身抗体阳性等。当存在以上情况上应怀疑是否存在APS。 2、诊断标准:血管内血栓形成和产科不良结局中具有任何一项和实验检测见狼疮抗凝物质及中到强滴度的抗心脂抗体IgG或IgM。 血管内血栓形成指任何器官或组织中发生不明原因的静脉、动脉或小血管内血栓形成。 产科不良结局是指孕10周后的≥1次原因不明的胎儿流失、孕10周后的≥3次复发性流产或孕34周前因重度子痫前期或胎盘功能低下而引起的早产。 实验检测需间隔6周的两次结果相同。 二、治疗: 妊娠期间的APS患者需在产科、风湿免疫科医师的共同管理下,严密随诊母体病情变化及胎儿的发育情况,加强监护。在孕28周之前至少每月复查一次,孕28周至36周至少每2周复查一次,36周之后每周复查,每次产检常规监测患者血压、体重、尿蛋白。治疗主要以防止血栓形成,对症处理为主,主要措施包括抗凝治疗、糖皮质激素、免疫抑制剂、丙种球蛋白等。 1、抗凝治疗:对出现血栓而血小板< 100 ×109/L,患者抗凝治疗应慎重。血小板< 50 ×109/L 的患者禁用抗凝治疗,可以应用激素联合大剂量丙种球蛋白静脉注射治疗,血小板上升后再予抗凝治疗。 (1)阿司匹林:对APA阳性,既往有胎儿生长受限、胎死宫内的孕妇,于妊娠12周以后

抗心磷脂综合征

抗磷脂综合征 ACA是抗磷脂抗体(antiphospholipikantibodies,APA)的成份之一。APA抗体是一组能与多种含有磷脂结构的抗原物质发生反应的抗体,其中包括狼疮抗凝物(lupusanticoagulant,LA),抗磷脂酸抗(anti-phosphatidi cacidantibody)和抗磷脂酰丝氨酸抗体(anti-phosphatidylserineantibody)等。 抗心磷脂是pangborn 1941年从牛的心肌中分离出来的一种具有肮原性的磷脂,并加以命名,其在哺乳动 物肌中含量最高,每个心磷脂分子包含4个不饱和的脂肪酸,极易氧化。ACA是与心磷脂分子中带负电荷的磷酸二酯基团结合,但这种结合必须要有心磷脂分子中的甘油酯部分,如果以苄环取代引甘油酯部分,心磷脂的抗原性则消失。ACA分子中的脂肪酸部分为其抗原性的必需成分;ACA与其它分子中带负荷的磷酸二酯基团并不结合,而只与磷脂分子中的该成分起反应。近年Hotkko等研究发现,ACA仅与已氧化的心磷脂结合,而并不能进行氧化的还原性的心磷脂类似物结合。Koike认为心磷脂与ACA的IgG结合需ACA的辅因子β2糖蛋白I(β2-GPI)的存在。Harris建立的ACA固相放射免疫法(RLA)所检出的ACA现认为是针对心磷脂与β2-GPI的复合体该法具有较高的敏感性,以后经Loizou等改良成与放射免疫法效果相同而更为方便的ELISA法。由于该法具有高度敏感性,可定量、可检测抗体类及亚类、易于标准化等优点,目前已成为定量测定ACA的世界性标准。ACA 的免疫学分型有IgG和IgA和IgM三类,ACA的发生率男女无明显差异。研究证实,许多因素与ACA产生密切相关,常见的原因有: (1)自身免疫性疾病:如系统性红斑狼疮(SLE)、类风湿性关节炎(RA)的硬皮病等; (2)病毒感染:如腺病毒、风疹病毒、水痘病毒、腮腺炎病毒等感染; (3)其它疾病:如支原体系统疾病等; (4)口服某些药物:如氯丙嗪、吩噻嗪等; (5)少数无明显气质性疾病的正常人,特别是老年人。 抗磷脂综合征概述 抗磷脂综合征抗磷脂综合征(anti-phospholipid s yndrome,APS)是指由抗磷脂抗体(APL抗体)引起的一组临床征象的总称,主要表现为血栓形成,习惯性流产,血小板减少等。在同一患者可仅有上述一种表现,也可同时有多种表现。APS是一种自身免疫性疾病,目前公认的诊断标准是病人具有下列临床特点之一:全身各脏器动、静脉血栓:复发性流产;胎儿死亡以及由于胎儿宫内窘迫提前分娩致新生儿死亡;自身免疫性血小板减少,上述临床表现同时伴有病人血清中出现APL包括抗心磷脂抗体(ACA)和狼疮凝血因子(LA)。在临床上由于抗心磷脂抗体的特异性更强,与上述临床表现关系更密切,因而也称为抗心磷脂综合征(anti-cardiolipin s yndrome, ACS)。APL是一组对机体带磷脂负电荷的蛋白复合物产生的特异性自身抗体,机体内某些血浆蛋白如β2糖蛋白(β2-GPI)的分子上带有ACA的抗原决定簇,ACA与β2-GPI结合后能识别带负电荷的磷脂复合物,并使β2-GPI的表面结构发生变化而出现被ACA识别的表位,β2-GPI具有抑制凝血酶原、抑制二磷酸腺苷(ADP)等引起的血小板聚集及其表面生成凝血酶、并阻滞磷脂依赖性凝血反应,当ACA与其反应后易形成血栓。因此,当A CL结合到细胞上通过蛋白上的结合磷脂诱发促凝活性,磷脂在APS栓塞的发生机理中起到系统性红斑狼疮(SL E)中出现这种综合征时称为继发性抗磷脂综合征,而在非SLE患者中出现者称为原发性磷脂综合征。 抗磷脂综合征临床表现 1、血栓形成 抗磷脂综合征中最突出表现是血栓形成,可以发生在动脉,也可在静脉。其中最常见是反复深静脉血栓、包括肾,视网膜和下腔静脉血栓,但对患者威胁更大是动脉血栓。在ACA阳性的SLE患者组织病理中发现非炎性阻塞性血管病变呈节段性,病变虽少,却很严重。心肌内动脉有纤维性血栓形成,并引起心肌梗塞,毛细血管和小动脉被纤维性物质阻塞,这些病理改变很可能都是APL抗体作用的结果。

2020年专家共识:产科抗磷脂综合征诊断与处理(完整版)

2020年专家共识:产科抗磷脂综合征诊断与处理(完整版) 共识要点 ●对于可疑APS 患者,建议同时检测LA、aCL 和anti-β2 GP ⅠAb,以确定血栓形成或产科并发症的风险。 ●目前对于标准诊断外的其他aPLs ,不建议常规检测。 ●持续中高滴度aPLs,以及LA、aCL、anti-β2 GP ⅠAb 阳性是影响APS 预后的主要因素。LA 阳性是影响APS 预后的独立危险因素,可用于APS 诊断和风险评估。 ●APS 患者有以下情况更易出现不良结局:中高风险的aPLs 谱;合并SLE 或其他全身性自身免疫性疾病;既往血栓形成史和病理妊娠史。 ●对于计划妊娠的OAPS 患者,建议每天应用LDA 50~100 mg 并维持整个妊娠期。对于常规治疗失败的OAPS、合并SLE 或其他全身性自身免疫性疾病、高风险aPLs 谱的OAPS,建议在妊娠前开始应用羟氯喹。

●对于OAPS 患者,在继续应用LDA 的基础上,妊娠后加用LMWH。LMWH 剂量和妊娠期维持时间应根据患者临床特征进行个体化处理。 ●对于常规治疗失败的OAPS,在妊娠前开始使用LDA 和羟氯喹的基础上,在妊娠期间加用小剂量泼尼松(孕早期≤10 mg/d)或同等剂量的糖皮质激素。 ●对于NOAPS,建议根据个体化风险(如aPLs 谱、伴有SLE、既往活产、妊娠丢失或血栓形成等),单独使用LDA 或联合使用LWMH。 ●对于妊娠前或妊娠早期已确诊的OAPS 患者,妊娠期aPLs 抗体滴度变化不作为药物剂量调整或停药的依据。 ●关于介入性产前诊断操作期间的抗凝治疗,LMWH 应在手术前至少12 h 暂停,并在穿刺后6~12 h 后恢复,以减少出血风险。 ●OAPS 并非剖宫产指征,如果没有其他产科并发症,推荐孕38~39 周计划分娩。如果合并子痫前期和胎盘功能不良的临床表现,应根据产科指征处理。 抗磷脂综合征(antiphospholipid syndrome, APS)是一种系统性自身免疫疾病,是以血栓形成和/ 或病理妊娠为主要临床特征,以及实

骨细胞相关因子在骨重建中的作用

骨细胞相关因子在骨重建中的作用 骨细胞是一种动态的、具有复杂功能的细胞,也是骨组织中含量最丰富、分布最广泛的细胞。近几年研究发现,骨细胞在骨重建中的调节作用越来越明显,其分泌的骨硬化蛋白、RANKL及OPG是调节骨形成和骨吸收的重要调控因子。骨细胞特异性地分泌的骨硬化蛋白对骨形成具有特殊的抑制效果,主要机制是结合LRP5/LRP6,从而阻止经典Wnt信号通路。而骨硬化蛋白的单克隆抗体则通过拮抗其作用而保证Wnt信号通路的正常传导,引起骨形成、骨密度和骨强度增加。骨细胞同样会分泌RANKL及OPG,两者在生理和病理条件下直接或间接调节破骨细胞分化和功能,调控骨重吸收。该文就这一领域近年研究现状和发展方向作一综述。 骨组织总是在连续不断地进行骨重建。两种类型细胞参与到骨重建,包括来源于血液系统的破骨细胞和来源于骨髓基质干细胞的成骨细胞和骨细胞。成骨细胞和破骨细胞在骨组织内只是短暂的存在,且数量少,位置不定。骨细胞则是骨组织中含量最丰富的细胞,在骨组织中形成遍布矿化骨基质的三维细胞网络。近几年研究发现,骨细胞在骨重建中的调节作用越来越明显,其分泌的骨硬化蛋白、RANKL及OPG是调节骨形成和骨吸收的重要调控因子。 1 骨细胞及其功能 骨细胞起源于成骨细胞,成熟成骨细胞的5%~20%包埋在自身分泌的基质中,并分化为骨细胞。成骨细胞的寿命是数周,破骨细胞仅为数天,而骨细胞的平均半寿期大约为25年[1]。这使骨细胞成为骨组织中数量最多的细胞,约占骨组织中细胞总数的90%以上。骨细胞目前被认为是骨组织中主要的应力感受器,其通过骨基质和骨陷窝-小管网络系统高度的连通性,能感知来自流体的各种力[2]。 骨细胞表达成骨细胞的大多数基因,包括成骨细胞特异性的转录因子和蛋白,尽管表达水平可能不尽相同。骨细胞中碱性磷酸酶和Ⅰ型胶原的表达较低,而骨钙蛋白表达较高。角膜蛋白在成骨细胞的表达显著高于骨细胞[3]。在骨组织矿化及磷酸代谢相关基因表达上骨细胞比成骨细胞富含更多基因,如PHEX、DMP1、MEPE、FGF23[4]。骨细胞既分泌磷蛋白质(如Dmp1),也参与骨基质的矿物质沉积[5]。骨细胞还参与体内磷酸盐平衡,作为磷元素和纤维原细胞因子(FGF)的主要供应者[5]。骨细胞也表达某些影响骨形成的分子微粒,包括Dkk1和SOST,但Dkk1也存在于成骨细胞,而SOST仅在骨细胞表达[4]。SOST 基因编码的骨硬化蛋白对骨形成蛋白(BMP)家族的成员蛋白具有很强的拮抗作用。此外,骨硬化蛋白和Dkk1与LRP5和LPR6结合,阻止Wnt信号通路的激活。此类研究表明骨细胞中少量表达的基因可能作为骨组织重建过程中的分子调解者。 2 骨细胞调节骨形成和骨吸收的分子机制

相关文档
最新文档